Eurand N.V. 

(Public, NASDAQ:EURX)   Watch this stock   
Find more results for EURX
Nov 10, 2009
EURAat Barclays Capital Healthcare Small-Cap One on One Conference
Nov 5, 2009
Q3 2009 EURAEarnings Conference Call
Nov 5, 2009
Q3 2009 EURAEarnings Release
Sep 21, 2009
EURAat UBS Global Life Sciences Conference
Sep 9, 2009
EURAat Thomas Weisel Partners Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -1.97% 13.83%
Operating margin 2.49% 17.16%
EBITD margin - 25.48%
Return on average assets -1.74% 11.20%
Return on average equity -2.37% 14.88%
Employees 563 -

Address

Olympic Plaza Fred. Roeskestraat 123
Amsterdam, 1076 EE
Netherlands
+31-20-6732744 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

Eurand N.V. discussed on blogs

Ranking 1300+ Small Cap Stocks by Cash Flow Per Share - NASD100 ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 2 hours ago

Eurand N.V. discussions

  View all discussions »

Description

Eurand N.V. (Eurand), formerly known as Eurand B.V., is a specialty pharmaceutical company. The Company develops, manufactures and commercializes pharmaceutical and biopharmaceutical products based on its drug formulation technologies. Through its collaboration arrangements, Eurand has applied its technologies to drug products in a range of therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition and respiratory. It develops and commercializes its own portfolio of products to address cystic fibrosis and gastrointestinal disorders. Eurand is an established business with manufacturing and research facilities in the United States, Italy and France. It manufactures and supplies over 40 different products for sale in pharmaceutical markets.

Officers and directors

Gearoid M. Faherty
Chairman of the Board, Chief Executive Officer, Executive Director
Age: 49
Bio & Compensation - Reuters
Mario P. Crovetto
Chief Financial Officer
Age: 55
Bio & Compensation - Reuters
Manya S. Deehr
Secretary, Chief Legal Officer
Age: 43
Bio & Compensation - Reuters
John J. Fraher
Chief Commercial Officer
Age: 43
Bio & Compensation - Reuters
Michael J. Walters
Executive Vice President - Sales and Marketing of Eurand Pharmaceuticals, Inc.
Age: 48
Bio & Compensation - Reuters
Ruth Thieroff-Ekerdt M.D.
Chief Medical Officer of Eurand Pharmaceuticals, Inc.
Age: 51
Bio & Compensation - Reuters
Robert Becker M.D.,
Chief Research Officer of Eurand SpA
Bio & Compensation - Reuters
William J. Jenkins M.D.
Non-Executive Director
Age: 61
Bio & Compensation - Reuters
Nicholas J. Lowcock
Non-Executive Director
Age: 45
Bio & Compensation - Reuters
Angelo C. Malahias
Non-Executive Director
Age: 47
Bio & Compensation - Reuters